Literature DB >> 10963085

Uveitis, an under-recognized adverse effect of pamidronate. Case report and literature review.

J Rey1, V Daumen-Legré, T Pham, P Bernard, L Dahan, P C Acquaviva, P Lafforgue.   

Abstract

Ophthalmologic adverse effects of bisphosphonate therapy are infrequent and of unclear pathogenesis. The most common has been anterior uveitis, of which 18 cases have been reported. Onset was within 24 to 48 hours after infusion initiation, and both eyes were affected in most patients. The outcome was favorable within a few days after bisphosphonate discontinuation and topical glucocorticoid therapy, although rechallenge was frequently followed by a recurrence. Bisphosphonates are being used successfully in an increasingly broad range of disorders. We report a case of pamidronate-induced anterior uveitis and present a review of the relevant literature.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10963085

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  6 in total

1.  Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.

Authors:  Beate Aurich Barrera; Lynda Wilton; Scott Harris; Saad A W Shakir
Journal:  Osteoporos Int       Date:  2005-08-31       Impact factor: 4.507

2.  Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England.

Authors:  Beate Aurich-Barrera; Lynda Wilton; Scott Harris; Saad A W Shakir
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 3.  Advances in the management of corticosteroid-induced osteoporosis with bisphosphonates.

Authors:  Johann D Ringe; Parvis Farahmand
Journal:  Clin Rheumatol       Date:  2006-11-23       Impact factor: 2.980

4.  A case report: zoledronic acid-induced anterior uveitis.

Authors:  Saadettin Kilickap; Yasemin Ozdamar; M Kadri Altundag; Omer Dizdar
Journal:  Med Oncol       Date:  2007-09-08       Impact factor: 3.064

5.  Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications.

Authors:  J-J Body; P Bergmann; S Boonen; J-P Devogelaer; E Gielen; S Goemaere; J-M Kaufman; S Rozenberg; J-Y Reginster
Journal:  Osteoporos Int       Date:  2012-02-04       Impact factor: 4.507

6.  Unilateral anterior uveitis complicating zoledronic acid therapy in breast cancer.

Authors:  Nagi S El Saghir; Zaher K Otrock; Jamal H Bleik
Journal:  BMC Cancer       Date:  2005-12-06       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.